Turkey is considered a successful transition model as a result of strong economic growth and less government control on foreign trade and investments. Turkeys pharmaceutical market is already the 14th largest globally and 4th largest in Asia, and the countrys Pharma 2023 Vision is likely to develop the local pharmaceutical industry even further.

  • What is Turkeys Pharma 2023 Vision and how will it promote local pharmaceutical manufacturing?

  • How successful was Turkeys 2003-2013 Health Transformation Program in improving the countrys healthcare system?

  • How will recent governmental reforms affect trade and investments in the pharmaceutical industry?

Our report offers in-depth insight into Turkeys macroeconomic environment, healthcare sector, pharmaceutical market, clinical trial industry, R&D activities, and recent business alliances & investments.

It provides you with a clear Roadmap for Business Growth based on the following proprietary tools:


EXECUTIVE SUMMARY

TABLES & GRAPHS

GLOSSARY

I.          COUNTRY OVERVIEW

II.        MACROECONOMIC & SOCIAL OUTLOOK

a.   MACROECONOMICS

b.   BUSINESS ENVIRONMENT

c.   SOCIAL OUTLOOK

III.       HEALTHCARE DEVELOPMENTS

a.   OVERVIEW

b.   PROVISION

c.   EXPENDITURE RATIOS

d.   PERSONNEL & INFRASTRUCTURE

e.   DISEASE BURDEN

IV.       MARKET ACCESS

a.   REGISTRATION

b.   PRICING & REIMBURSEMENT

V.        PHARMACEUTICAL OUTLOOK

a.   OVERVIEW

b.   PHARMACEUTICAL MARKET

c.   LEADING PHARMACEUTICAL COMPANIES

d.   MANUFACTURING & TRADE

VI.       COMPLIANCE

a.   MARKETING PRACTICES

b.   CLINICAL TRIALS

VII.     RESEARCH & DEVELOPMENT

a.   R&D FUNDS BY SOURCE

b.   PHARMA SHARE IN R&D

VIII.    CROs / CLINICAL TRIALS

IX.       ALLIANCES & INVESTMENTS

X.        CONCLUDING REMARKS

Table 1. Demographics in Turkey, 2013
Table 2. Health system indicators before 2000 and after the Health Transformation Program
Table 3. Inventory of medical devices in Turkey, 2011
Table 4. Pharmaceutical prices in Turkey, 2012

Figure 1: Breakdown of government expenditures, 2012
Figure 2: FDI inflows by country, 2012
Figure 3: FDI inflows by sector, 2012
Figure 4: Healthcare expenditures, 2012
Figure 5: Major causes of death, 2009
Figure 6: Pharmaceutical sales by therapeutic class, 2012
Figure 7: Share of drug sales by category, 2013
Figure 8: Drug market trends, 2010-2016
Figure 9: Leading pharmaceutical companies in Turkey, 2012
Figure 10: Production of pharmaceuticals and medicinal chemicals, 2006-2012
Figure 11: Share of imported & locally produced drugs in the Turkish pharma market, 2013
Figure 12: Pharmaceutical trade, 2006-2012
Figure 13: Pharmaceutical import partners, 2013
Figure 14: Pharmaceutical export partners, 2013
Figure 15: Technology & Innovation grants by technology field, 2012
Figure 16: R&D funds by source, 2012
Figure 17: Number of scientific publications in Turkey, 2002-2011
Figure 18: R&D profile, 2011
Figure 19: Registered clinical trials by phase, 2008-2012
Figure 20: Clinical trials by therapeutic area, 2012
Figure 21: Clinical trial approval process

Order Report

Please fill out the form below. A sales representative will
get back to you very shortly.

First Name*

E-mail Address*

Company*

Country*

Requested Report

Last Name*

Phone Number*

Position*

City*

Verification*

Details